U.S. Markets closed

Tetraphase Pharmaceuticals, Inc. (TTPH)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
7.90+0.02 (+0.25%)
At close: 4:00PM EDT
People also watch
CEMPCMRXPTCTESPRZFGN

Tetraphase Pharmaceuticals, Inc.

480 Arsenal Street
Suite 110
Watertown, MA 02472
United States
617-715-3600
http://www.tphase.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees66

Key Executives

NameTitlePayExercisedAge
Mr. Guy MacDonald B.ScChief Exec. Officer, Pres and Director724.1k76.73k58
Mr. Christopher WattSr. VP of Fin.378.72kN/A52
Dr. Jacques Dumas Ph.D.Chief Scientific Officer508.56kN/A51
Ms. Maria D. StahlSr. VP and Gen. Counsel456.56kN/A46
Dr. Patrick T. Horn M.D., Ph.D.Chief Medical Officer532.12kN/A62
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. Its lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The company has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy. It is also developing TP-271, a preclinical compound that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a second-generation Gram-negative program, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. In addition, the company is involved in the discovery and development of additional antibiotics for the treatment of unmet medical needs, including multidrug-resistant Gram-negative bacteria. Tetraphase Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Tetraphase Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 7. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.